Terlipressin (Glypressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepato-renal syndrome type 1. It is a prodrug and is converted to the lysine vasopressin in the circulation after the N-triglycyl residue is cleaved by endothelial peptidases. This results in a ‘slow release’ of the vasoactive lysine vasopressin. Terlipressin exerts its action by activating V1a, V1b and V2 vasopressin receptors.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P37288 Gene ID: 552.0 Gene Symbol: AVPR1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27586252 |
852.0 nM [Ki] | ||
Target ID: P47901 Gene ID: 553.0 Gene Symbol: AVPR1B Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27586252 |
1115.0 nM [Ki] | ||
Target ID: P30518 Gene ID: 554.0 Gene Symbol: AVPR2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27586252 |
1580.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | GLYPRESSIN Approved UseGLYPRESSIN is used to treat Bleeding Oesophageal Varices (BOV), bleeding veins in
the lower end of the food-pipe in people with serious liver disease. GLYPRESSIN is also used to treat hepatorenal syndrome, type 1 (HRS-1). |
|||
Primary | GLYPRESSIN Approved UseGLYPRESSIN is used to treat Bleeding Oesophageal Varices (BOV), bleeding veins in
the lower end of the food-pipe in people with serious liver disease. GLYPRESSIN is also used to treat hepatorenal syndrome, type 1 (HRS-1). |
PubMed
Title | Date | PubMed |
---|---|---|
European Society of Intensive Care Medicine 14th annual congress, 30 September-3 October 2001, Geneva, Switzerland. | 2001 Dec |
|
Life, death, and varices. | 2001 Nov |
|
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. | 2002 Apr |
|
Update on ascites and hepatorenal syndrome. | 2002 Aug |
|
Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. | 2002 Dec |
|
Terlipressin-induced vasoconstriction reversed with N-acetylcysteine: a case for combined use in hepatorenal syndrome? | 2002 Dec |
|
Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. | 2002 Feb |
|
Double-blind randomized, comparative multicenter study of the effect of terlipressin in the treatment of acute esophageal variceal and/or hypertensive gastropathy bleeding. | 2002 Jul-Aug |
|
Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis. | 2002 Nov |
|
Terlipressin and arterial blood volume after paracentesis for tense ascites in cirrhosis. | 2002 Nov |
|
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. | 2002 Oct |
|
Terlipressin for haemodynamic support in septic patients: a double-edged sword? | 2002 Oct 19 |
|
[Comparison of Doppler ultrasonography and hepatic venous pressure gradient in assessing portal hypertension in liver cirrhosis]. | 2002 Sep |
|
Management of acute variceal bleeding. | 2003 |
|
[Drug therapy of portal hypertension]. | 2003 Apr |
|
Terlipressin and albumin for the hepatorenal syndrome. | 2003 Apr |
|
Comparison of Doppler ultrasonography and the hepatic venous pressure gradient in assessing portal hypertension in liver cirrhosis. | 2003 Apr |
|
Terlipressin and albumin combination treatment in hepatorenal syndrome. | 2003 Dec |
|
Portal hypertensive bleeding. | 2003 Dec |
|
Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats. | 2003 Dec |
|
Terlipressin in chronic hyperdynamic endotoxic shock: is it safe? | 2003 Feb |
|
[Hepatorenal syndrome: from physiopathology to treatment]. | 2003 Jan |
|
Patient with a sudden drop in blood pressure. | 2003 Jan |
|
Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. | 2003 Jan |
|
Systematic review: terlipressin in acute oesophageal variceal haemorrhage. | 2003 Jan |
|
Hepatorenal syndrome. | 2003 Jan-Mar |
|
When endoscopic therapy or pharmacotherapy fails to control variceal bleeding: what should be done? Immediate control of bleeding by TIPS? | 2003 Jul |
|
Cyclooxygenase expression in splanchnic hyposensitivity to glypressin of bleeding portal hypertensive rats. | 2003 Jun |
|
Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors. | 2003 Jun |
|
Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. | 2003 May |
|
Comment on "Terlipressin in chronic hyperdynamic endotoxic shock: is it safe?" by P. Asfar. | 2003 May |
|
Terlipressin infusion in catecholamine-resistant shock. | 2003 Oct |
|
[Vasopressin and its analogues in the therapy of shock]. | 2004 |
|
Vasopressors for shock. | 2004 |
|
[Acute upper gastrointestinal variceal bleeding: vasoactive agents]. | 2004 Apr |
|
Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. | 2004 Apr |
|
Effects of terlipressin on systolic pulmonary artery pressure of patients with liver cirrhosis: an echocardiographic assessment. | 2004 Aug 1 |
|
Somatostatin, somatostatin analogues and other vasoactive drugs in the treatment of bleeding oesophageal varices. | 2004 Feb |
|
Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. | 2004 Feb 27 |
|
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. | 2004 Jan |
|
Role of vasopressin in the management of septic shock. | 2004 Jul |
|
Pressure or flow? | 2004 Jun |
|
Clinical review: influence of vasoactive and other therapies on intestinal and hepatic circulations in patients with septic shock. | 2004 Jun |
|
Terlipressin for cerebral perfusion pressure support in a patient with septic shock. | 2004 Jun |
|
[Refractory hypotension during anesthesia in a patient treated with angiotensin receptor blockers]. | 2004 Jun-Jul |
|
A long-acting vasopressin analog for septic shock: brilliant idea or dangerous folly? | 2004 Mar |
|
Terlipressin for catecholamine-resistant septic shock in children. | 2004 Mar |
|
Effect of terlipressin on blood volume distribution in patients with cirrhosis. | 2004 May |
|
A prospective double blind randomized study comparing the need for blood transfusion with terlipressin or a placebo during early excision and grafting of burns. | 2004 May |
|
Terlipressin in patients with septic shock: friend or foe? | 2004 May |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.nps.org.au/__data/cmi_pdfs/CMR10462.pdf
The maximum dose is 1.7 mg given every 4 hours for up tp 48 hours (bleeding oesophageal varices) or every 6 hours for up to 2 weeks (hepatorenal syndrome, type 1).
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8835750
Isolated perfused mesenteric arteries of portal vein ligated and sham-operated rats were contracted by methoxamine (3 nmol-3 mumol) and then treated with nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (100 microM), terlipressin or the selective V2 receptor agonist desmopressin (each 0.5 uM). Terlipressin alone reduced and in combination with NG-nitro-L-arginine methyl ester abolished the difference in reactivity to methoxamine between the portal vein ligated and sham-operated groups.
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 17 10:43:46 UTC 2022
by
admin
on
Sat Dec 17 10:43:46 UTC 2022
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
7Z5X49W53P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
580417
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
||
|
FDA ORPHAN DRUG |
534216
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
||
|
FDA ORPHAN DRUG |
11785
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
||
|
WHO-VATC |
QH01BA04
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
||
|
FDA ORPHAN DRUG |
191804
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
||
|
WHO-ATC |
H01BA04
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
||
|
NCI_THESAURUS |
C80212
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2135460
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
7Z5X49W53P
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
TERLIPRESSIN
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
7Z5X49W53P
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
238-680-8
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
C77387
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
57048
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | RxNorm | ||
|
14636-12-5
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
SS-34
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
M10580
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | Merck Index | ||
|
C012078
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
SUB10927MIG
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
DTXSID7048952
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
2967
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
5114
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
72081
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY | |||
|
DB02638
Created by
admin on Sat Dec 17 10:43:46 UTC 2022 , Edited by admin on Sat Dec 17 10:43:46 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
Believed to behave as a prodrug
IN-VIVO
PLASMA
|
||
|
METABOLITE ACTIVE -> PARENT |
IN-VIVO
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:SEQUENCE(CALCULATED) | CHEMICAL |
|
||||
Molecular Formula | CHEMICAL |
|